Adverse Events of Special Interest within COVID-19 Subjects
=============

<img src="https://img.shields.io/badge/Study%20Status-Started-blue.svg" alt="Study Status: Started">

- Analytics use case(s): **Characterization**
- Study type: **Clinical Application**
- Tags: **COVID-19**
- Study lead: **Erica A Voss**
- Study lead forums tag: **[ericaVoss](https://forums.ohdsi.org/u/ericaVoss)**
- Study start date: **November 2, 2021**
- Study end date: **-**
- Protocol: [AESIs in COVID-19 Subjects Protocol](https://ohdsi-studies.github.io/Covid19SubjectsAesiIncidenceRate/Protocol.html)
- Publications: **-**
- Results explorer: **-**

Extending on our previous work by Li et al. [1](https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceRate) [2](https://pubmed.ncbi.nlm.nih.gov/33791732/) in understanding the incidence rates of adverse events of special interest (AESI) for COVID-19, this work will look at the rates of these AESIs in patients who had COVDI-19 disease.

# Requirements
TBD

# How to Run
TBD

# License 
The Covid19SubjectsAesiIncidenceRate package is licensed under Apache License 2.0.

# Development

Covid19SubjectsAesiIncidenceRate was developed in ATLAS and R Studio.
